Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Intel Corporation (INTC) -- Ignore unavailable to you. Want to Upgrade?

To: Tony Viola who wrote (107546)	8/14/2000 8:18:01 PM
From: EricRR	Respond to of 186894

A while ago someone told me what stepping was. Now Scumbria has told me what a speedpath is. I wouldn't venture onto an Amgen thread, or something like that, and start challenging how they were going about researching the human genome, just because I can spell it. I would, because Amgen has claimed that the gene patents which protect certain drugs which influence a protein coded by that gene, also cover any drugs which target a regulator of that gene. While the protein coded by a single gene is unique, it's regulation may not be, and certainly knowledge of such is not required to get the original patent. Amgen's claim is clearly ridiculous, because through the same logic, casscading effects and feedback would allow almost any single gene patent to claim a whole swath of cellular activities.